A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.
背景 京都大学医学部附属病院血液内科（高折晃史教授）とCiRA（江藤浩之教授）のグループは、これまでに患者自身のiPS細胞由来血小板(注２)を使った臨床研究を実施してきました。この臨床研究は自家移植であり、...
背景 京都大学医学部附属病院血液内科（高折晃史教授）とCiRA（江藤浩之教授）のグループは、これまでにiPS細胞由来血小板（注２）を使った臨床研究を実施し、iPS細胞由来の血小板製剤の安全性について検証を行...
Development, manufacturing, and sales of automatic feeding vessels and related equipment for aquaculture farms.
A Globally Recognized Deep-Tech Company Developing Robotics and AI: We are a rare, cutting-edge technology venture based in Osaka, Japan, known for integrating robotics and AI to create customized solutions tailored to specific industry needs. Our technologies have been adopted by over 100 leading organizations across sectors such as construction, disaster response, infrastructure, railways, electric power, automotive, heavy industry, steel, maritime, and healthcare. Trusted for our problem-solving capabilities, we have earned a strong reputation across diverse industries. Prestigious institutions, including MIT, have visited us to study our advanced technologies.
Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
Cerebro Pharma was established in 2020 as an Osaka-based bio-venture with the mission to create a society free of dementia. We focus on research and development of healthcare products and pharmaceuticals specializing in the prevention and improvement of dementia and neurodegenerative diseases, and actively promote collaborative projects with major domestic pharmaceutical companies and academic institutions.